CD8A and cancer: In a study of advanced MCC patients who received first-line pembrolizumab (NCT02267603), oncoprotein-specific CD8 T cells tracked with responsiveness wherein responders (n = 13) had more abundant cancer-specific T cells in blood at baseline compared to non-responders (n = 4) (38).